# First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

> **NCT05188859** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 29 (estimated)

## Conditions studied

- Mesothelioma, Malignant
- Mesothelioma, Malignant Pleural
- Mesothelioma Malignant Advanced

## Interventions

- **DRUG:** Sintilimab+Anlotinib+Pemetrexed+Cisplatin

## Key facts

- **NCT ID:** NCT05188859
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188859, "First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05188859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*